Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma

被引:305
作者
Montoto, Silvia
Davies, Andrew John
Matthews, Janet
Calaminici, Maria
Norton, Andrew J.
Amess, John
Vinnicombe, Sarah
Waters, Rachel
Rohatiner, Ama Z. S.
Lister, T. Andrew
机构
[1] Canc Res UK, Med Oncol Unit, Barts & London Queen Marys Sch Med & Dent, London, England
[2] Barts & London NHS Trust, Dept Cellular Pathol, London, England
[3] Barts & London NHS Trust, Dept Haematol, London, England
[4] Barts & London NHS Trust, Dept Radiol, London, England
[5] Univ Oxford, Canc Res UK Med Stat Grp, Oxford, England
关键词
D O I
10.1200/JCO.2006.09.3260
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To study the clinical significance of transformation to diffuse large B-cell lymphoma (DLBCL) in patients with follicular lymphoma (FL). Patients and Methods From 1972 to 1999, 325 patients were diagnosed with FL at St Bartholomew's Hospital (London, United Kingdom). With a median follow-up of 15 years, progression occurred in 186 patients and biopsy-proven transformation in 88 of the 325. The overall repeat biopsy rate was 70%. Results The risk of histologic transformation (HT) by 10 years was 28%, HT not yet having been observed after 16.2 years. The risk was higher in patients with advanced stage (P = .02), high-risk Follicular Lymphoma International Prognostic Index (FLIPI; P = .01), and International Prognostic index (IPI; P = .04) scores at diagnosis. Expectant management (as opposed to treatment being initiated at diagnosis) also predicted for a higher risk of HT (P = .008). Older age (P = .005), low hemoglobin level (P = .03), high lactate dehydrogenase (P < .0001), and high-risk FLIPI (P = .01) or IN (P = .003) score at the time of first recurrence were associated with the diagnosis of HT in a biopsy performed at that time. The median survival from transformation was 1.2 years. Patients with HT had a shorter overall survival (P < .0001) and a shorter survival from progression (P < .0001) than did those in whom it was not diagnosed. Conclusion Advanced stage and high-risk FLIPI and IN scores at diagnosis correlate with an increased risk of HT. This event strongly influences the outcome of patients with FL by shortening their survival. There may be a subgroup of patients in whom HT does not occur.
引用
收藏
页码:2426 / 2433
页数:8
相关论文
共 33 条
[21]  
HUBBARD SM, 1982, BLOOD, V59, P258
[22]   PATTERNS OF SURVIVAL IN PATIENTS WITH RECURRENT FOLLICULAR LYMPHOMA - A 20-YEAR STUDY FROM A SINGLE-CENTER [J].
JOHNSON, PWM ;
ROHATINER, AZS ;
WHELAN, JS ;
PRICE, CGA ;
LOVE, S ;
LIM, J ;
MATTHEWS, J ;
NORTON, AJ ;
AMESS, JAL ;
LISTER, TA .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) :140-147
[23]   COMPARISON OF 3 SERUM ALPHA-HYDROXYBUTYRATE DEHYDROGENASE PROCEDURES FOR LACTATE-DEHYDROGENASE ISOENZYME DISCRIMINATION [J].
LEUNG, FY ;
HENDERSON, AR .
CLINICA CHIMICA ACTA, 1981, 115 (02) :145-153
[24]   CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma [J].
Marcus, R ;
Imrie, K ;
Belch, A ;
Cunningham, D ;
Flores, E ;
Catalano, J ;
Solal-Celigny, P ;
Offner, F ;
Walewski, J ;
Raposo, J ;
Jack, A ;
Smith, P .
BLOOD, 2005, 105 (04) :1417-1423
[25]   Survival after progression in patients with follicular lymphoma:: analysis of prognostic factors [J].
Montoto, S ;
López-Guillermo, A ;
Ferrer, A ;
Camós, M ;
Alvarez-Larrán, A ;
Bosch, F ;
Bladé, J ;
Cervantes, F ;
Esteve, J ;
Cobo, F ;
Colomer, D ;
Campo, E ;
Montserrat, E .
ANNALS OF ONCOLOGY, 2002, 13 (04) :523-530
[26]   Role of image-guided core-needle biopsy in the management of patients With lymphoma [J].
Pappa, VI ;
Hussain, HK ;
Reznek, RH ;
Whelan, J ;
Norton, AJ ;
Wilson, AM ;
Love, J ;
Lister, TA ;
Rohatiner, AZS .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (09) :2427-2430
[27]   CONSERVATISM OF APPROXIMATION SIGMA (O - E)2/E IN LOGRANK TEST FOR SURVIVAL DATA OR TUMOR INCIDENCE DATA [J].
PETO, R ;
PIKE, MC .
BIOMETRICS, 1973, 29 (03) :579-584
[28]   A PREDICTIVE MODEL FOR AGGRESSIVE NON-HODGKINS-LYMPHOMA [J].
SHIPP, MA ;
HARRINGTON, DP ;
ANDERSON, JR ;
ARMITAGE, JO ;
BONADONNA, G ;
BRITTINGER, G ;
CABANILLAS, F ;
CANELLOS, GP ;
COIFFIER, B ;
CONNORS, JM ;
COWAN, RA ;
CROWTHER, D ;
DAHLBERG, S ;
ENGELHARD, M ;
FISHER, RI ;
GISSELBRECHT, C ;
HORNING, SJ ;
LEPAGE, E ;
LISTER, TA ;
MEERWALDT, JH ;
MONTSERRAT, E ;
NISSEN, NI ;
OKEN, MM ;
PETERSON, BA ;
TONDINI, C ;
VELASQUEZ, WA ;
YEAP, BY .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (14) :987-994
[29]   Follicular lymphoma international prognostic index [J].
Solal-Céligny, P ;
Roy, P ;
Colombat, P ;
White, J ;
Armitage, JO ;
Arranz-Saez, R ;
Au, WY ;
Bellei, M ;
Brice, P ;
Caballero, D ;
Coiffier, B ;
Conde-Garcia, E ;
Doyen, C ;
Federico, M ;
Fisher, RI ;
Garcia-Conde, JF ;
Guglielmi, C ;
Hageenbeek, A ;
Haïoun, C ;
LeBlanc, M ;
Lister, AT ;
Lopez-Guillermo, A ;
McLaughlin, P ;
Milpied, N ;
Morel, P ;
Mounier, N ;
Proctor, SJ ;
Rohatiner, A ;
Smith, P ;
Soubeyran, P ;
Tilly, H ;
Vitolo, U ;
Zinzani, PL ;
Zucca, E ;
Montserrat, E .
BLOOD, 2004, 104 (05) :1258-1265
[30]   THERAPY OF RELAPSED OR REFRACTORY LOW-GRADE FOLLICULAR LYMPHOMAS - FACTORS ASSOCIATED WITH COMPLETE REMISSION, SURVIVAL AND TIME TO TREATMENT FAILURE [J].
SPINOLO, JA ;
CABANILLAS, F ;
DIXON, DO ;
KHORANA, SM ;
MCLAUGHLIN, P ;
VELASQUEZ, WS ;
HAGEMEISTER, FB ;
REDMAN, JR ;
SWAN, F .
ANNALS OF ONCOLOGY, 1992, 3 (03) :227-232